PreludeDx Receives FDA Breakthrough Device Designation for AidaBREAST® - Early-Stage Invasive Breast Cancer Assay

AidaBREAST designation marks PreludeDx's second FDA Breakthrough Device, following DCISionRT® LAGUNA HILLS, Calif., April 29, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug...